文献速递眼底病与葡萄膜炎

合并nAMD的地图样萎缩患者接受抗VEGF与pegcetacoplan联合治疗的一年结果

ONE-YEAR RESULTS OF GEOGRAPHIC ATROPHY PATIENTS WITH PREEXISTING nAMD TREATED WITH BOTH ANTI-VEGF THERAPY AND PEGCETACOPLAN.
PubMed 文献 · Retina · 2026-01-01

回顾性队列研究纳入31例既往接受抗VEGF治疗至少1年、后联合pegcetacoplan治疗的nAMD合并GA患者。黄斑中心凹下GA被排除。平方根转换后GA面积在pegcetacoplan启动前1年增长+0.39 mm,启动后1年增长+0.22 mm,增长率降低44%(P < 0.0001)。视力保持稳定,2年内从67.5个字母变为67.9个字母(P = 0.93)。

要点

  • 联合治疗期间GA面积增长率较治疗前降低44%(P < 0.0001)。
  • 视力在2年观察期内保持稳定(67.5至67.9个ETDRS字母,P = 0.93)。
  • 研究排除了黄斑中心凹下GA患者,结论外推需谨慎。

核心结论

  • 抗VEGF与pegcetacoplan联合治疗与GA病灶增长率总体降低相关,并使nAMD稳定。

研究设计与样本

  • 回顾性队列研究,纳入31例nAMD合并GA患者,时间为2023年3月至2025年7月。
  • 纳入标准为既往抗VEGF治疗至少1年,且随后一年内同时接受抗VEGF和pegcetacoplan治疗。
  • 排除黄斑中心凹下GA患者。
  • 使用SD-OCT、红外反射、眼底自发荧光和眼底照相在5个时间点测量GA面积。
  • 采用线性混合效应模型分析平方根转换后的GA面积纵向变化。

主要发现

  • 抗VEGF平均治疗间隔11.8周,pegcetacoplan平均治疗间隔8.1周。
  • nAMD平均治疗时长6.5年。
  • 平方根转换GA面积从-1年至pegcetacoplan启动增加+0.39 mm,从启动至+1年增加+0.22 mm,增长率降低44%(P < 0.0001)。
  • 视力从67.5个字母增至2年后的67.9个字母(P = 0.93)。

临床怎么用

  • 对既往有nAMD且合并GA(非中心凹下)的患者,可考虑抗VEGF与pegcetacoplan联合治疗以减缓GA进展。
  • 治疗期间需定期监测GA面积和视力变化。

局限性

  • 回顾性研究设计,样本量较小(31例)。
  • 排除了黄斑中心凹下GA患者,结果不适用于该亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine geographic atrophy (GA) progression in patients receiving pegcetacoplan injections with preexisting neovascular age-related macular degeneration (nAMD) treated previously and concurrently with anti-VEGF (vascular endothelial growth factor) injections. METHODS: Retrospective cohort study of 31 nAMD and coexisting GA patients from March 2023 to July 2025. Inclusion criteria were previous anti-VEGF treatment for ≥1 year and concurrent anti-VEGF and pegcetacoplan treatments in the following year. Subfoveal GA patients were excluded. Spectral-domain optical coherence tomography, infrared reflectance data, fundus autofluorescence, and fundus photography were used to measure GA area at five time points: 1 year before pegcetacoplan initiation and then every 6 months until 1 year after pegcetacoplan initiation. Longitudinal change in GA area was analyzed using a linear mixed-effects model with square-root transformed GA area to account for repeated measurements within eyes. Visual acuity was recorded and converted to Early Treatment Diabetic Retinopathy Study (ETDRS) letters for analysis. RESULTS: Twelve patients were male and 19 female, with an average age of 87.2 years. Mean anti-VEGF treatment interval was 11.8 weeks, and 8.1 week for pegcetacoplan. Average treatment duration of nAMD was 6.5 years. Square-root transformed GA area increased +0.39 mm from -1 year to pegcetacoplan initiation, then +0.22 mm from initiation to +1 year, a 44% decrease in GA growth rate ( P < 0.0001). Visual acuity remained stable, starting at 67.5 letters, increasing to 67.9 letters after 2 years ( P = 0.93). CONCLUSION: Concurrent anti-VEGF and pegcetacoplan therapy was associated with an overall reduction in GA lesion growth rate and stabilized nAMD.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Adrean SD, Han W, Hui J, et al. ONE-YEAR RESULTS OF GEOGRAPHIC ATROPHY PATIENTS WITH PREEXISTING nAMD TREATED WITH BOTH ANTI-VEGF THERAPY AND PEGCETACOPLAN. Retina. 2026. PMID: 42467820. doi:10.1097/IAE.0000000000004915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。